Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus rituximab versus placebo plus rituximab in previously untreated follicular lymphoma
MOH_2017-07-05_000596Phase 3Active, not recruiting
- Sponsor
- Pharmacyclics
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibrutinib and rituximab in follicular lymphoma (FL) (4 arms), sponsored by Pharmacyclics. Primary endpoint: Progression-free survival. Started Apr 2017; status: active, not recruiting.
02
Drugs
ibrutinibrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2017-07-05_000596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-05_000596.